Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care

Oncologist

Volumn 10, Issue 10, 2005, Pages 833-841

  Sleijfer, Stefan ^a   Seynaeve, Caroline ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adults; Chemotherapy; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; MESNA; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; STREPTOZOCIN; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE; VINDESINE;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SOFT TISSUE SARCOMA; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SARCOMA;

EID: 31444432831     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-833     Document Type: Review

References (50)

1. [No authors listed.] Adjuvant chemotherapy for localized resectable softtissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-Analysis Collaboration. Lancet 1997;350:1647-1654.
2. Blay J-Y, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003;39:64-69.
3. Chang P, Wiernik PH. Combination chemotherapy with doxorubicin and streptozocin. I. Clinical results in patients with advanced sarcoma. Clin Pharmacol Ther 1976;20:605-610.
4. Schoenfeld DA, Rosenbaum C, Horon J et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycine-D and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757-2762.
5. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987;5:840-850.
6. Omura GA, Major FJ, Blessing JA et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcoma. Cancer 1983;52:626-632.
7. Muss HB, Bundy B, DiSaia J et al. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648-1653.
8. Borden EC, Amato DA, Edmonson JH et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas. Cancer 1990;66:862-867.
9. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
10. Santoro A, Tursz T, Mouridsen HT et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
11. O'Bryan RM, Baker LH, Gottlieb JE et al. Dose-response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-1948.
12. Judson I, Radford JA, Harris M et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877.
13. Nielsen OS, Dombernowsky P, Mouridsen HT et al. High-dose epirubicin is not an alternative of standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998;78:1634-1639.
14. van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-2406.
15. Nielsen OS, Judson I, van Hoesel Q et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000;36:61-67.
16. Buesa JM, Mouridsen HT, van Oosterom AT et al. High-dose DTIC in advanced sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-309.
17. Verweij J, Lee SM, Ruka W et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2081-2086.
18. Bramwell VH, Mouridsen HT, Santoro A et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization of Research and Treatment Cancer (EORTC), Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993;31(suppl 2):S180-S184.
19. Okuno S, Ryan LM, Edmonson JH et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). Cancer 2003;97:1969-1973.
20. Švancárová L, Blay JY, Judson IR et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556-559.
21. Balcerzak SP, Benedetti J, Weiss GR et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995;76:2248-2252.
22. Gian VG, Johnson TJ, Marsch RW et al. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue or bone sarcomas. J Exp Ther Oncol 1996;1:186-190.
23. Woll PJ, Judson I, Lee SM et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999;35:410-412.
24. Muss HB, Bundy BN, Adcock L et al. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:32-34.
25. Brennan MF, Alektiar KM, Maki RG. Soft tissue sarcoma. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 6th Ed. Philadelphia: Lippincott Williams & Wilkins 2001:1841-1891.
26. Budd GT, Rankin C, Hutchins LF et al. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Invest New Drugs 2002;20:129-132.
27. van Glabbeke M, Steward W, Armand JP. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer 2002;38:635-638.
28. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adults with locally advanced or metastatic soft tissue sarcoma. The Cochcrane Database of Systematic Reviews 2001;4.
29. Jelic S, Kovcin V, Milanovic N et al. Randomized study of high-dose epirubicin versus high-dose epirubicin and cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220-225.
30. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
31. Baker LH, Frank J, Fine G et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin-D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III Southwest Oncology Group Study (7613). J Clin Oncol 1987;5:851-861.
32. Pinedo HM, Bramwell VH, Mouridsen HT et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984;53:1825-1832.
33. Le Cesne A, Judson I, Crowther D et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization of Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2000;18:2676-2684.
34. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005;23:105-112.
35. van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1999;17:150-167.
36. van Glabbeke M, Verweij J, Judson J et al. Progression-free rate as the principal end point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002;38:543-549.
37. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-2037.
38. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
39. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: a randomised trial. Lancet 2004;364:1127-1134.
40. McArthur GA, Demetri GD, van Oosterom AT et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005;23:866-873.
41. Verweij J, van Oosterom A, Blay J-Y et al. Imatinib mesylate (STI-571, Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
42. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
43. Nielsen OS, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-1307.
44. Tomek S, Koestler W, Horak P et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003;39:1318-1329.
45. van Oosterom AT. Phase II new drug trials in soft tissue sarcomas. In: Pinedo H and Verweij J, eds. Clinical Management of Soft Tissue Sarcomas. Boston: Martinus Nijhoff Publishers, 1986:131-138.
46. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary end-point. Control Clin Trials 2000;21:343-359.
47. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization of Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576-584.
48. Thall PF, Wathen JK, Bekele N et al. Hierarchical bayesian approaches to phase II tr ials in diseases with multiple subtypes. Stat Med 2003;2003:763-780.
49. Rosner GL, Stadler W, Ratkin MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-4484.
50. van den Abbeele AD, Badawi RD, Manola J et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. Proc Annual Meeting Am Soc Clin Oncol 2004;3012a.